NY-SECURITYSCORECARD
SecurityScorecard, the global leader in cybersecurity ratings, today announced the results of its new report, Addressing the Trust Deficit In Critical Infrastructure, which revealed 48% of critical manufacturing organizations ranked “C,” “D,” or “F” on SecurityScorecard’s security ratings platform. Published during the World Economic Forum (WEF) Annual Meeting, the report analyzed the current state of cyber resilience in the critical infrastructure sectors such as Energy, Chemical, Healthcare, and others, as designated by the Cybersecurity and Infrastructure Security Agency (CISA). Organizations with an “A” security rating are 7.7 times less likely to sustain a breach than those with an “F” rating.
“Security ratings are a trusted barometer of cyber resilience and the time is now for policymakers and organizations to make cyber risk measurement mandatory,” said Aleksandr Yampolskiy, co-founder and CEO of SecurityScorecard. “Cyberattacks in the last 10 years have gotten much worse, more complex, and increasingly have targeted critical infrastructure, thereby undermining the public’s trust in the cyber resilience of our global economy.”
SecurityScorecard provides comprehensive security ratings, automated assessments, and guidance from industry experts, providing a patented and easy-to-understand A-F graded scorecards for improved communication, effective compliance reporting, and more informed decision-making.
According to the World Economic Forum, only 19% of cyber leaders feel confident that their organizations are cyber resilient. SecurityScorecard recently joined the World Economic Forum Global Innovators Community, contributing to WEF’s Centre for Cybersecurity’s initiative to address systemic challenges, improve trust, and build cyber resilience. Yampolskiy is attending the WEF Annual Meeting in Davos to engage with the world’s foremost public- and private-sector leaders on mitigating global cyber risk, including within critical infrastructure.
Critical Manufacturing Patching Cadence Falls Amid Escalating Attack Cadence
Cyber incidents affecting critical infrastructure, once comparatively rare, have become far more frequent in recent years as nation-states and their proxies escalate their pursuit of geopolitical objectives. Data from the Federal Bureau of Investigation showed that 14 of the 16 sectors considered critical infrastructure by the U.S. government experienced at least one ransomware attack in 2021.
SecurityScorecard assessed these industries to measure their current state of cyber resilience. It found that critical manufacturing is highly vulnerable based on analysis of all organizations under that category in The Forbes Global 2000 list. SecurityScorecard considers 10 factors when developing an organization’s security rating. Of those 10, the patching cadence ‘factor’ for critical manufacturing experienced a significant drop from 2021 to 2022, moving from 88 (B) to 76 (C).
High and Medium-Severity CVEs Strain Resources
The decline in patching is likely due to an increased volume of vulnerabilities. Critical manufacturing experienced a 38% year-over-year increase in high severity vulnerabilities. In 2022 alone, 76% of critical manufacturing organizations have high and medium-severity CVEs.
These CVEs may, in some cases, facilitate ransomware groups’ targeting of organizations in the sector. Manufacturers experienced an increase in malware infections from 2021 to 2022. In 2022, 37% of critical manufacturing organizations had malware infections.
“While investing in more technology might seem burdensome to resource-constrained critical infrastructure operators, the reality is that cybersecurity ratings technology is extremely cost-effective, especially when you consider the catastrophic cost of a breach is $9.44 million on average for U.S. organizations,” continued Yampolskiy. “By leveraging security ratings, these organizations have a simple way to build resilience and make more informed decisions to strengthen their cyber defenses by confidently measuring risk and quantifying the trustworthiness of their partners, contractors, third-and fourth-party vendors, and supply chains.”
To view the full research paper, please visit: https://resources.securityscorecard.com/davos-2023/addressing-the-trust-deficit
About SecurityScorecard
Funded by world-class investors including Evolution Equity Partners, Silver Lake Waterman, Sequoia Capital, GV, Riverwood Capital, and others, SecurityScorecard is the global leader in cybersecurity ratings with more than 12 million companies continuously rated. Founded in 2013 by security and risk experts Dr. Aleksandr Yampolskiy and Sam Kassoumeh, SecurityScorecard's patented rating technology is used by over 30,000 organizations for enterprise risk management, third-party risk management, board reporting, due diligence, cyber insurance underwriting, and regulatory oversight. SecurityScorecard is the first cybersecurity ratings company to offer digital forensics and incident response services, providing a 360-degree approach to security prevention and response for its worldwide customer and partner base. SecurityScorecard continues to make the world a safer place by transforming the way companies understand, improve and communicate cybersecurity risk to their boards, employees and vendors. Every organization has the universal right to their trusted and transparent Instant SecurityScorecard rating. For more information, visit securityscorecard.com or connect with us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005416/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
